These studies are forerunners of future work focusing on characterizing the entire TIF and plasma secretome in triple negative breast cancers, within the context of the ER/PR status of breast cancers, to understand the mechanisms that drive the aggressiveness of breast cancers and their resistance to treatment. The gene discussed is ESR1; the disease is breast carcinoma.